Gene Therapy Market Size, Forecast, Analysis & Share Surpass US$ 5.3 Billion | 2028, at 19.8% CAGR 

According to the report, the global gene therapy market was valued at US$ 1.3 Bn in 2020 and is expected to reach the value of US$ 5.3 Bn at a CAGR of 19.8% from 2021 to 2028. Gene therapy is a way of fixing genetic disorders by introducing a normal and healthy gene in place of the defective one in a cell to prevent or cure different types of genetic and chronic disorders for which no cure has been developed. Gene therapy is considered an important mode of treatment, as it helps eliminate the usage of drugs, surgery, or other procedures, which can have side effects. Several clinical research studies are being conducted to develop effective gene therapy products for the treatment of diseases related to ophthalmology, oncology, and ADA-SCID.

Gene therapy in ophthalmology includes the injection of fully functional genes into the retinal cells in order to allow restoration of normal gene expression. Different gene therapy approaches are being studied in the fields of oncology, such as pro-drug activating suicide gene therapy, anti-angiogenic gene therapy, oncolytic virotherapy, and gene therapy-based immune modulation. The adenosine deaminase (ADA)‐deficient severe combined immunodeficiency (SCID) is a very rare form of congenital disorder of the immune system.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐰𝐢𝐭𝐡 𝐆𝐫𝐚𝐩𝐡𝐬 & 𝐋𝐢𝐬𝐭 𝐨𝐟 𝐅𝐢𝐠𝐮𝐫𝐞𝐬 𝐚𝐭 (𝐔𝐬𝐞 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐌𝐚𝐢𝐥 𝐈𝐝 𝐟𝐨𝐫 𝐐𝐮𝐢𝐜𝐤 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞) - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1838

𝐏𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐎𝐮𝐭𝐜𝐨𝐦𝐞𝐬 𝐭𝐨 𝐃𝐫𝐢𝐯𝐞 𝐌𝐚𝐫𝐤𝐞𝐭

Gene therapy has considerable potential to eliminate and prevent several genetic disorders and numerous life-threatening disorders, especially cancer, heart diseases, AIDS, cystic fibrosis, and age-related disorders. Gene therapy provides a complete cure to patients affected with genetic disorders, rather than ease symptoms with other therapeutic treatments. The first gene therapy product 'Gendicine' was developed by Shenzhen, China-based SiBiono GeneTech Co. Ltd. in 2003 and was commercialized in 2004 for the treatment of head and neck cancer. Since 2004, more than 30,000 patients have been treated with Gendicine in China. Gendicine has exhibited notable safety results, and when this gene therapy is combined with other treatment forms, such as chemotherapy and radiotherapy, the overall outcome outperforms other standard therapies alone.

Patients treated with Novartis AG's gene therapy product Kymriah have exhibited a remission rate of 81% with three months of treatment, and all the patients who exhibit a positive response to treatment were not detected with any minimal residual disease. Hence, the overall promising results of gene therapy fuels the demand for gene therapy products.

𝐍𝐞𝐰 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 & 𝐂𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝐏𝐫𝐨𝐩𝐞𝐥 𝐌𝐚𝐫𝐤𝐞𝐭

The years 2016, 2017, and 2018 were key milestones in the history of the gene therapy market in the U.S. and Europe because around four gene therapy products have been approved and commercialized. These products are currently in a nascent stage of commercialization, and have exhibited highly positive therapeutic outcomes. Increase in competition among the leading biopharmaceutical companies to approve and commercialize gene therapy products in different areas of unmet medical needs to gain the first mover advantage is likely to boost the growth of the gene therapy market during the forecast period.

𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐢𝐧 𝐍𝐮𝐦𝐛𝐞𝐫 𝐨𝐟 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐂𝐞𝐧𝐭𝐞𝐫𝐬 𝐭𝐨 𝐀𝐮𝐠𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭

New gene therapy product approvals and potential success rates of gene therapy have led to an increased demand for more number of treatment centers in the U.S. and Europe. The companies, after initial success rates of gene therapy, strive to increase the number of treatment centers in order to gain access to a large patient pool requiring gene therapy treatments.

The gene therapy product Kymriah, which was approved for the treatment of patients up to the age of 25 years affected with large B-cell lymphoma, has only 41 treatment centers in the U.S., which limits a large number of patients from receiving gene therapy treatment.

𝐁𝐮𝐲 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 | 𝐈𝐦𝐦𝐞𝐝𝐢𝐚𝐭𝐞 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐭 - https://www.transparencymarketresearch.com/checkout.php?rep_id=1838<ype=S

𝐏𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐚𝐧𝐝 𝐇𝐢𝐠𝐡 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐢𝐧 𝐑&𝐃

Significant investments in gene-related research & development by various biopharmaceutical companies, governments, and research institutes presents an opportunity to gain the first mover advantage in the gene therapy market. A large number of gene therapy products are under different stages of clinical studies, and the number of gene therapy candidates is projected to rise during the forecast period. High investment in gene therapy research and large number of late stage gene therapy candidates in the oncology domain and other genetic disorders are projected to fuel the demand for gene therapy products during the forecast period.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐨𝐧 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

The global cell culture market is consolidated in terms of number of players. Key players in the global market includes Novartis AG, Orchard Therapeutics Limited, Celgene Corporation, Spark Therapeutics, Inc., Gilead Sciences, Inc., Sibiono GeneTech Co. Ltd., and Other prominent players.

𝐆𝐥𝐨𝐛𝐚𝐥 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧

𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐏𝐫𝐨𝐝𝐮𝐜𝐭

Instruments
Media
Sera
Reagents

𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐛𝐲 𝐄𝐧𝐝-𝐮𝐬𝐞𝐫

Biotechnology Companies
Pharmaceutical Companies
Academic Institutes
Research Institutes

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 -

𝐅𝐮𝐧𝐝𝐮𝐬 𝐂𝐚𝐦𝐞𝐫𝐚𝐬 𝐌𝐚𝐫𝐤𝐞𝐭- https://www.prnewswire.com/news-releases/fundus-cameras-market-to-reach-valuation-of-us-810-4-mn-by-2027--says-tmr-301520905.html

𝐍𝐞𝐮𝐫𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭- https://www.globenewswire.com/news-release/2022/04/25/2428360/0/en/Neurological-Disorder-Drugs-Market-to-Expand-with-Rise-in-Focus-of-Players-on-Development-of-3D-CNS-Organoids-States-TMR-Study.html

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.